Adaptive Radiotherapy for Safe Hypofractionation
This study is testing a new way of giving radiotherapy, called adaptive radiotherapy, for people with prostate, endometrial, cervical, or rectal cancer. Standard radiotherapy treatment often uses many small doses over a longer period. This new method, called 'hypofractionated' adaptive radiotherapy, uses fewer, higher doses over a shorter time. Because it uses daily scans to adjust the treatment, it can be more precise, potentially reducing side effects on healthy tissues. The main goal is to check if this new approach is as safe as current treatments, looking closely at side effects. Researchers will also be checking how well it tackles the cancer and how it affects patients' quality of life.
At a glance
What is this study about?
Imagine you have cancer and need radiotherapy. Standard radiotherapy usually involves lots of small treatment sessions. This is a very effective treatment, but because our bodies can shift slightly day to day, doctors often have to treat a slightly larger area than just the tumour to make sure they don't miss anything. This can sometimes lead to healthy tissues nearby getting some radiation, which might cause side effects.
This study is looking at a new, more advanced type of radiotherapy called 'adaptive radiotherapy.' Think of it like this: before each treatment, a special scanner checks exactly where your tumour is and if any surrounding organs have moved slightly that day. Then, the treatment plan is quickly adjusted on the spot to make sure the radiation is aimed precisely at the cancer, avoiding healthy tissues as much as possible. Because it's so precise, doctors believe they might be able to give fewer, stronger doses of radiation, which could mean fewer hospital visits for you.
The main purpose of this study is to see if this new, more flexible treatment delivers radiation just as safely as the standard method, especially in terms of side effects. We also want to see if it works just as well at treating the cancer, how it affects your quality of life, and if it makes treatment more efficient. This research could help us find better, more patient-friendly ways to treat cancer in the future.
Key takeaways
- Compares standard radiotherapy with a new 'adaptive' method.
- Aims to make radiotherapy more precise and potentially reduce side effects.
- Focuses on prostate, endometrial, cervical, and rectal cancers.
- Investigating if fewer, stronger radiation doses are safe and effective.
- Monitors side effects, cancer control, and patient well-being.
- You would be randomly assigned to one of the two treatment groups.
Who may be eligible?
To join this study, you would first need to be registered in a special patient database called the PERa registry. Being part of this registry means you've already agreed to be contacted about research studies and to potentially be a 'control' participant if needed.
The study is for people with several types of cancer that affect the pelvic area, such as prostate, endometrial, cervical, and rectal cancer. Both men and women can take part, and there are no age limits mentioned.
However, there are a few reasons why some people might not be able to join, especially if they have prostate cancer. For example, if you have a medical device like a pacemaker, or certain metal implants in your hip that would interfere with MRI scans, or if you get very anxious in enclosed spaces (claustrophobia) and can't have an MRI, this study might not be suitable for you.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you already registered in the PERa patient database?
- Do you have endometrial, cervical, or rectal cancer?
- If you have prostate cancer, are you able to have an MRI scan?
- Do you not have metal implants in your hip or other pelvic metalwork that might interfere with scans?
What does participation involve?
If you join this study, you will be randomly assigned to one of two groups, like flipping a coin. One group will receive the standard radiotherapy treatment that is currently used. The other group will receive the new 'adaptive hypofractionated radiotherapy.'
Both groups will have regular hospital visits for their radiotherapy sessions. If you're in the adaptive radiotherapy group, you'll have a scan before each treatment, and your plan will be adjusted based on that day's scan. The exact number of visits, assessments, and follow-ups will depend on your specific cancer type and the radiotherapy schedule you receive. The researchers will closely monitor any side effects and how well the treatment is working. You will also be asked about your quality of life.
Potential risks and benefits
Locations (1)
- Centre Hospitalier de l'Université de MontréalVerified postcodeMontreal, Canada
Common questions
What does 'hypofractionated' mean?
It means receiving fewer, larger doses of radiation over a shorter period, compared to more, smaller doses over a longer time.
What is 'adaptive radiotherapy'?
It's a modern way of giving radiotherapy where the treatment plan is adjusted daily based on scans taken just before your session, to make it as precise as possible.
Will I know which treatment I'm getting?
Yes, you would be told which treatment group you are in – either the standard radiotherapy or the new adaptive radiotherapy.
What types of cancer are included?
This study is for people with prostate, endometrial, cervical, or rectal cancer.
Can I leave the study if I change my mind?
Yes, you can choose to leave the study at any point, and your medical care will not be affected.
How to find out more
Mom Phat
Always speak to your GP or specialist before deciding to take part in a study.
Interested in taking part?
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.